NVIDIA & Eli Lilly launch $1 billion AI Lab to reinvent drug discovery

4Moving Biotech bags FDA nod to launch US trial of groundbreaking osteoarthritis therapy

Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function

NAMSA expands US footprint with Labcorp medical device testing acquisition

The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof

Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis

The FDA designation follows visual-function results from the Phase 2 ACUITY trial

FibroBiologics moves experimental psoriasis therapy into FDA review

The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline

Sinopia Biosciences scores NIH grant to supercharge AI-driven drug discovery

The funding will accelerate Sinopia’s data-driven drug discovery efforts

MARAbio launches first blood test to detect maternal autoantibody-linked autism

The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water

Gut health crisis fuelling anxiety, early ageing & lifestyle diseases

The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing

Godavari Biorefineries launches US biotech arm to advance novel cancer therapies

The move strengthens GBL’s clinical-stage presence in the United States

FDA nods spotlight precision oncology platforms as market surges towards $212 billion by 2034

The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034